Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model

Zhang, Yuning; Liu, Chao; Wang, Tao; Kong, Fanxuan; Zhang, Huan; Yi, Jing; Dong, Xiwen; Duan, Han; Ning, Tao; Yang, Yuefeng; Wang, Hua

doi:10.1016/j.omto.2022.01.007

Cited by 9 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, 40% of the patients had bone metastases, and even after a short 9-week follow-up time, 27% of the patients showed PSA reduction (59). Further results were reported in ASCO genitourinary meeting in 2022 with similar findings, demonstrating that in a mCRPC cohort that included 44% of patients with bone metastases, 23% of all mCRPC patients had complete response and 16% had partial response (60). Even though the data does not yet indicate response rates separately for bone metastatic patients, the observed 40% of patients with bone metastases will hopefully lead to discussing the issue when the full results of the phase II study are published.…”

Section: Talabostat Mesylatesupporting

confidence: 78%

Insights into immuno-oncology drug development landscape with focus on bone metastasis

Kähkönen,

Halleen,

MacRitchie

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Bone is among the main sites of metastasis in breast, prostate and other major cancers. Bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life. Despite the success of immunotherapies in oncology, no immunotherapies are approved for bone metastasis and no clear benefit has been observed with approved immunotherapies in treatment of bone metastatic disease. Therefore, it is crucial to consider unique features of tumor microenvironment in bone metastasis when developing novel therapies. The vicious cycle of bone metastasis, referring to crosstalk between tumor and bone cells that enables the tumor cells to grow in the bone microenvironment, is a well-established concept. Very recently, a novel osteoimmuno-oncology (OIO) concept was introduced to the scientific community. OIO emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, and it can be used to reveal the most promising targets for bone metastasis. In order to provide an insight into the current immuno-oncology drug development landscape, we used 1stOncology database, a cancer drug development resource to identify novel immunotherapies in preclinical or clinical development for breast and prostate cancer bone metastasis. Based on the database search, 24 immunotherapies were identified in preclinical or clinical development that included evaluation of effects on bone metastasis. This review provides an insight to novel immuno-oncology drug development in the context of bone metastasis. Bone metastases can be approached using different modalities, and tumor microenvironment in bone provides many potential targets for bone metastasis. Noting current increasing interest in the field of OIO, more therapeutic opportunities that primarily target bone metastasis are expected in the future.

show abstract

Section: Talabostat Mesylatesupporting

confidence: 78%

Insights into immuno-oncology drug development landscape with focus on bone metastasis

Kähkönen,

Halleen,

MacRitchie

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Contrastingly, when decorin was loaded to oncolytic adenoviruses on mesenchymal stem cells, the inhibition of anti-inflammatory cytokines was abolished. As such, it seems that decorin’s role in inflammation depends on the cellular interactions it establishes ( 71 ).…”

Section: The Role Of Ecm In Tumor Immunitymentioning

confidence: 99%

Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy

Collado,

Boland,

Ahrendsen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Glioblastoma (GBM) accounts for approximately half of all malignant brain tumors, and it remains lethal with a five-year survival of less than 10%. Despite the immense advancements in the field, it has managed to evade even the most promising therapeutics: immunotherapies. The main reason is the highly spatiotemporally heterogeneous and immunosuppressive GBM tumor microenvironment (TME). Accounting for this complex interplay of TME-driven immunosuppression is key to developing effective therapeutics. This review will explore the immunomodulatory role of the extracellular matrix (ECM) by establishing its contribution to the TME as a key mediator of immune responses in GBM. This relationship will help us elucidate therapeutic targets that can be leveraged to develop and deliver more effective immunotherapies.

show abstract

“…Ad-Ad5/3-TRAIL BM-MSCs Pancreatic ductal adenocarcinoma IV [175] Ad-hTERTp-IL24 WJ-MSCs Hepatocellular carcinoma IV [176] Ad-5-E3, Ad-WNTi BM-MSCs Hepatocellular carcinoma IV [177,178] Ad-CRAd-EGFP BM-MSCs Colon cancer IV, IP [17] Ad-CRAd, Ad-bic MSCs-E1 (Gene Ad E1A/E1B) Prostate cancer IT [179] Ad-CRAd, Ad5/3.CXCR4 BM-MSCs Lung metastases of breast carcinoma IV [180] Ad-CRAdNTR (PS1217H6) BM-MSCs Colorectal cancer IV [181] Ad-CRAd5/F11 Men-MSCs Colorectal cancer IV, IP, IT [182] AD-5/3-kBF5HRE-E1Awt BM-MSCs Melanoma, breast tumour IO [183] Ad-WT, Ad-RGD, Ad-5/3, Ad-CRAd Source of MSCs non-specified Gliomas (Glioblastoma multiforme) IC [184] Ad-WT, Ad-5-CRAd-S-pk7 BM-MSCs Breast cancer IT [185] Ad-rAd.DCN Ad-rAd.Null WJ-MSCs Breast cancer lung metastatic IV [186] Ad5-Delta-24-RGD Source of MSCs non-specified Ovarian and breast cancer IV [187] Ad-Delta-24-RGD BM-MSCs Gliomas IC, IA [188][189][190] Ad5/35-Tet-on-E1b Pro-D24-ES-IL-24 UCB-MSCs Gliomas IV [191] Ad-YSCH-01 DP-MSCs Glossopharyngeal, bladder and breast squamous cancer IV, IP, IT [192] Herpesviridae Human…”

Section: Adenoviridae Humanmentioning

confidence: 99%

Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects

Gil-Chinchilla,

Zapata,

Moraleda

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are one of the most widely used cell types in advanced therapies due to their therapeutic potential in the regulation of tissue repair and homeostasis, and immune modulation. However, their use in cancer therapy is controversial: they can inhibit cancer cell proliferation, but also potentially promote tumour growth by supporting angiogenesis, modulation of the immune milieu and increasing cancer stem cell invasiveness. This opposite behaviour highlights the need for careful and nuanced use of MSCs in cancer treatment. To optimize their anti-cancer effects, diverse strategies have bioengineered MSCs to enhance their tumour targeting and therapeutic properties or to deliver anti-cancer drugs. In this review, we highlight the advanced uses of MSCs in cancer therapy, particularly as carriers of targeted treatments due to their natural tumour-homing capabilities. We also discuss the potential of MSC-derived extracellular vesicles to improve the efficiency of drug or molecule delivery to cancer cells. Ongoing clinical trials are evaluating the therapeutic potential of these cells and setting the stage for future advances in MSC-based cancer treatment. It is critical to identify the broad and potent applications of bioengineered MSCs in solid tumour targeting and anti-cancer agent delivery to position them as effective therapeutics in the evolving field of cancer therapy.

show abstract

Therapeutic effects of mesenchymal stem cells loaded with oncolytic adenovirus carrying decorin on a breast cancer lung metastatic mouse model

Cited by 9 publications

References 48 publications

Insights into immuno-oncology drug development landscape with focus on bone metastasis

Insights into immuno-oncology drug development landscape with focus on bone metastasis

Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy

Bioengineered Mesenchymal Stem/Stromal Cells in Anti-Cancer Therapy: Current Trends and Future Prospects

Contact Info

Product

Resources

About